secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2026-08-13T12:32:09+00:00
Accession:  0001628280-26-056497
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Q2 2026 net loss $15M; soticlestat rights sold to Perceptive NewCo for up to $294.5M milestones
--------------------------------------------------------------------------------

- Cash $169.8M at June 30, 2026; runway into 2029.
- Net loss $15.0M ($0.08/share) vs $4.7M ($0.06) in Q2 2025; R&D spend up to $10.0M.
- OV329 Phase 2 FOS study initiated; photosensitivity study testing 5/7/9 mg doses, results near year-end 2026.
- Soticlestat global rights assigned to Perceptive NewCo; Ovid eligible for up to $294.5M milestones plus low-to-mid single-digit royalties.
- Leadership: Kevin Norrett CBO, Charles Carter CFO, Eliseo Salinas R&D Advisor; warrants exercised for ~$53.9M proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828026056497/0001628280-26-056497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828026056497/ovid-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-056497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer